PMC7337879_01
Mean change in BRVA and CMT from baseline at 1, 2 and 3 years' follow-up in patient 1 (A) and patient 2 (B) post-FAc implantation. BRVA, best-recorded visual acuity; CMT, central macular thickness; FAc, fluocinolone acetate.
bmjophth-2020-000484f04.jpg
PMC7337879_02_bmjophth-2020-000484f04.jpg
F4
Intravitreal injection of FAc implant was conducted in the left eye on 27 May 2014 (figure 4B). In patient 1, this gain was maintained (15 letter gain) over 36 months from a baseline of 61.1 letters, while patient 2 had a gain in BRVA from a lower baseline BRVA of 35 letters to 61.1 letters by month 12 (26 letter gain), which was then maintained up to 36 months (figure 4A). CMT reduced to <300 microm at month 1 (patient 1) and month 3 (patient 2) and this was maintained through to month 36. Considerable reduction in CMT was observed during the follow-up period, from a baseline of 699 mum to 224 mum at month 36 in patient 1 and from 620 mum to 189 mum at month 36 in patient 2 (figure 4B).
PMC7337879_02
Mean change in BRVA and CMT from baseline at 1, 2 and 3 years' follow-up in patient 1 (A) and patient 2 (B) post-FAc implantation. BRVA, best-recorded visual acuity; CMT, central macular thickness; FAc, fluocinolone acetate.
bmjophth-2020-000484f04.jpg
PMC7337879_02_bmjophth-2020-000484f04.jpg
F4
Intravitreal injection of FAc implant was conducted in the left eye on 27 May 2014 (figure 4B). In patient 1, this gain was maintained (15 letter gain) over 36 months from a baseline of 61.1 letters, while patient 2 had a gain in BRVA from a lower baseline BRVA of 35 letters to 61.1 letters by month 12 (26 letter gain), which was then maintained up to 36 months (figure 4A). CMT reduced to <300 microm at month 1 (patient 1) and month 3 (patient 2) and this was maintained through to month 36. Considerable reduction in CMT was observed during the follow-up period, from a baseline of 699 mum to 224 mum at month 36 in patient 1 and from 620 mum to 189 mum at month 36 in patient 2 (figure 4B).